Piper Sandler Maintains Overweight on TransMedics Group, Raises Price Target to $160
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Piper Sandler analyst Matt O'Brien maintains TransMedics Group (NASDAQ:TMDX) with a Overweight and raises the price target from $140 to $160.
Piper Sandler analyst Matt O'Brien maintains TransMedics Group (NASDAQ:TMDX) with a Overweight and raises the price target from $140 to $160.